Developer docs
API playgroundTry for free, no card

Search company profiles

Neopharma Technologies

Full company profile

uuid0005g1l

Namestring
Neopharma Technologies
Legal namestring
Neopharma Technologies
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Neopharma Technologies is a Perth, Australia-based SaaS company that provides a digital Fit-for-Duty platform combining workplace drug and alcohol testing with cognitive and psychomotor impairment screening for safety-critical industries. The company targets organizations in mining, resources, ports, marine, and aviation ground operations where contractor-heavy workforces and multi-site deployments require consistent, documented impairment risk management. Its customer base spans direct enterprise accounts, third-party administrators (TPAs), drug testing device distributors, and testing device manufacturers served through an OEM channel model.

The core product, NEOVAULT, is a device-agnostic point-of-care platform that captures drug and alcohol test results through smartphone or tablet applications and produces digital chain-of-custody records and audit-ready compliance documentation. The platform incorporates NEO-Vision computer vision technology for automated interpretation of oral fluid, urine, and breath alcohol test results, and integrates with DRUID, a one-minute functional impairment assessment that compares cognitive and psychomotor performance against individual personal baselines. The NEOTEST product range includes purpose-built hardware (Tamperloks, Split Cups, Multi-Panel Cups, Dip Cards, Oral Fluid tests) that operate natively within the NEOVAULT ecosystem. The platform holds ISO 27001, SOC 2 Type II, HIPAA, and GDPR certifications and integrates with EHS platforms including HSI Donesafe via API.

Neopharma operates a multi-revenue-stream model combining SaaS subscriptions (NEOVAULT/DRUID enterprise licensing) with hardware sales (NEOTEST kits) and OEM/API distribution through EHS platform and device-manufacturer partners. The go-to-market is enterprise-focused with quote-based pricing, direct field sales, and an API-first channel strategy. The company maintains offices in Perth (headquarters), Utah (USA), and Kuala Lumpur (Malaysia), with operational footprint across Australia, the United States, Canada, and Malaysia. The company is pursuing a NASDAQ listing as of late 2025, with Singapore fintech veteran Joo Seng Wong appointed as Board Advisor to oversee institutional strategy and global execution.

Short descriptiontext

Neopharma Technologies provides a SaaS platform combining workplace drug and alcohol testing with AI-driven cognitive impairment screening for safety-critical industries including mining, ports, and aviation. The Perth-based company serves enterprises and channel partners across Australia, the US, and Southeast Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPerth, Australia
HQ citystring
Perth
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
workplace drug testing, impairment screening software, fit-for-duty compliance, EHS platform integration, digital chain of custody
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Workplace Drug Testing Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS Platform Subscription
TypeSubscription Recurring
Description

Cloud-based platform subscription for access to NEOVAULT and DRUID software. Includes dashboard access, API integrations, workflow management, and reporting capabilities. Subscription tiers likely based on organization size, number of sites, and feature requirements.

neopharmatechnologies.com
2NEOTEST Testing Kits
TypeHardware Sales
Description

Sale of NEOTEST branded drug and alcohol testing devices including oral fluid tests, urine cups, dip cards, split cups, and Tamperloks devices. Devices are sold as NEOVAULT-enabled units with integrated software capability.

neopharmatechnologies.com
3Enterprise Licensing
TypeSubscription Recurring
Description

Enterprise licensing for large multi-site organizations requiring standardized Fit-for-Duty workflows across multiple locations and contractor groups. Includes configuration, integration, and deployment services.

neopharmatechnologies.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure
Pricing details1 tier
1Enterprise SaaS platform pricing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

neopharmatechnologies.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1NEOVAULT
Description

Digital drug testing and chain of custody platform for workplace fit-for-duty assessment

neopharmatechnologies.com
+3 more records
Core offering1 text field

Neopharma Technologies develops and sells NEOVAULT®, a device-agnostic point-of-care SaaS platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening for enterprise Fit-for-Duty workforce management. The platform combines AI-powered automated result interpretation (NEO-Vision), digital chain of custody, and multi-site enterprise scalability. It is complemented by the DRUID® impairment screening module and the NEOTEST® range of physical testing devices (oral fluid, urine cups, dip cards, split cups, Tamperloks) designed to operate natively within the NEOVAULT ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Complete digital chain of custody, eliminating paper-based documentation
+3 more records
Product overview1 text field

Neopharma Technologies offers NEOVAULT®, a device-agnostic point-of-care platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening into a unified Fit-for-Duty solution. The core NEOVAULT® platform is supported by add-on modules including NEO-Vision (AI image recognition for automated result interpretation), Digital Chain of Custody, Fit-for-Duty Decisioning, Enterprise Scalability, Compliance and Governance, BrAC Recording, and Digital Drug Testing workflows. The companion DRUID® module provides one-minute functional impairment assessment measuring cognitive and psychomotor performance against individual baselines. The NEOTEST® product family includes purpose-built testing devices (Tamperloks, Split Cups, Multi-Panel Cups, Dip Cards, Oral Fluid tests) that are NEOVAULT®-enabled out of the box. The combined NEOVAULT® + DRUID® ecosystem delivers comprehensive workforce impairment management for safety-critical environments.

Product and service7 records
1NEOVAULT®
CategoryCore SaaS Platform
Description

Device-agnostic point-of-care SaaS platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening. Uses a smartphone or tablet app to capture and process test results in real time, creating a defensible digital audit trail with automated chain of custody, escalation rules, and compliance governance for enterprise workforce Fit-for-Duty programs.

2DRUID® Impairment Screening
CategoryImpairment Screening Module
Description

One-minute functional impairment assessment delivered via smartphone or tablet. Measures cognitive and psychomotor performance (reaction time, processing speed, hand-eye coordination, balance, short-term processing capacity) against individual personal baselines to detect impairment from fatigue, illness, stress, medication, or substances. Each worker establishes a personal baseline through three supervised practice tests.

3Tamperloks Drug Testing Cup
CategoryPhysical Testing Device
Description

Tamper-proof urine drug testing cup with interlocking lid and seal, unique triple chamber design that is 100% leak and odor proof. Includes temperature test strip and adulteration detection. Digitally enabled via NEOVAULT app with dynamic QR code and electronic chain of custody integration.

4Drug Test Split Cup
CategoryPhysical Testing Device
Description

Dual specimen chamber urine test cup that simultaneously screens for up to 7 drugs and retains specimens for confirmation testing. Features leak-resistant hinged lid, angled opening, and specimen temperature indication with qualitative results in 5 minutes.

5Multi Panel Drug Test Cups
CategoryPhysical Testing Device
Description

All-in-one urine-based multi-drug test cup supporting 1 to 14 panels per specifications. Quick, precise solution for on-site drug screening with results in minutes. FDA cleared and CLIA waived.

6Dip Card Drug Tests
CategoryPhysical Testing Device
Description

CLIA Waived and FDA 510(k) cleared all-in-one urine-based drug test in dip card format. Supports 1 to 6 panels with simple non-invasive procedure and fast results in 5 minutes. Complies with AS/NZS 4308:2008 Australian Standard.

7Drug Test Oral Fluid
CategoryPhysical Testing Device
Description

Oral fluid drug test complying with AS4760:2019 Australian Standard. Simple, fast, accurate detection of recent illicit drug use. Supports 1 to 14 panels and detects commonly abused drugs at concentrations below 75 ng/mL with non-invasive sample collection.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-24
Description

API integration embedding Neopharma's NEOVAULT Fit-For-Duty workflows and DRUID impairment assessment into HSI Donesafe's cloud-based EHS safety management platform. The integration consolidates drug and alcohol testing and functional impairment assessments within the same governance system used for safety reporting, replacing fragmented checks with connected controls and strengthening audit trails. Addresses Australian WHS regulatory requirements.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-01
Description

Partnership to integrate NEOVAULT digital drug test reporting with AI-powered cognitive impairment assessment tools. Combines Neopharma's drug and alcohol testing platform with Impairment Science's cognitive assessment capabilities for comprehensive Fit-for-Duty screening.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Dräger
TypeBroad incumbent
Description

German multinational manufacturer of safety and medical technology, including the DrugTest 5000 oral fluid drug testing system and Alcotest breath alcohol devices used in workplace and law enforcement settings. Directly comparable in workplace drug and alcohol testing hardware, with Dräger operating as a much larger incumbent across broader industrial safety.

TypeEmerging player
Description

Remote alcohol monitoring device and cloud platform used in legal, employment, and recovery contexts. Comparable digital impairment monitoring technology with similar enterprise and B2B workplace applications, though narrower in scope to alcohol rather than full substance and cognitive screening.

TypeDirect peer
Description

Specialized drug testing laboratory offering hair, urine, and oral fluid testing for workplace, legal, and clinical markets. Comparable substance testing focus with similar turnaround-time and chain-of-custody requirements.

TypeDirect peer
Description

Manufacturer of oral fluid diagnostic products including the Intercept drug testing device used in workplace and clinical settings. Directly comparable in vitro diagnostic substance manufacturing focused on oral fluid drug detection and workplace testing applications.

TypeBroad incumbent
Description

Global diagnostics and medical device company with significant workplace drug testing operations through its eScreen and Alere Toxicology platforms. Comparable enterprise SaaS and drug testing offering but with a much broader diagnostics and device portfolio.

TypeBroad incumbent
Description

Major US medical laboratory services company with substantial employer solutions and workplace drug testing services. Comparable substance testing services but at much larger scale and with broader clinical and anatomic pathology focus.

TypeDirect peer
Description

Specialized hair drug testing laboratory providing workplace drug testing services to employers. Comparable substance testing focus with an alternative sample type and similar employer-customer profile.

TypeDirect peer
Description

Canadian workplace drug and alcohol testing service provider offering fitness-for-duty assessments for employers across industrial sectors. Directly comparable employer-focused drug and impairment testing offering, primarily serving the Canadian market.

TypeDirect peer
Description

Workplace drug testing and behavioral health services provider offering substance testing, medication monitoring, and behavioral health programs for employers and the justice system. Comparable employer drug testing services with overlapping customer base in safety-sensitive industries.

TypeDirect peer
Description

US-based manufacturer of urine and oral fluid drug testing devices, including multi-panel cups and dip cards used at point of care. Directly comparable drug testing device manufacturing with focus on workplace and clinical point-of-care products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neopharma Technologies

Workplace Drug Testing Softwareneopharmatechnologies.com

Neopharma Technologies provides a SaaS platform combining workplace drug and alcohol testing with AI-driven cognitive impairment screening for safety-critical industries including mining, ports, and aviation. The Perth-based company serves enterprises and channel partners across Australia, the US, and Southeast Asia.

What Neopharma Technologies does

Neopharma Technologies is a Perth, Australia-based SaaS company that provides a digital Fit-for-Duty platform combining workplace drug and alcohol testing with cognitive and psychomotor impairment screening for safety-critical industries. The company targets organizations in mining, resources, ports, marine, and aviation ground operations where contractor-heavy workforces and multi-site deployments require consistent, documented impairment risk management. Its customer base spans direct enterprise accounts, third-party administrators (TPAs), drug testing device distributors, and testing device manufacturers served through an OEM channel model.

The core product, NEOVAULT, is a device-agnostic point-of-care platform that captures drug and alcohol test results through smartphone or tablet applications and produces digital chain-of-custody records and audit-ready compliance documentation. The platform incorporates NEO-Vision computer vision technology for automated interpretation of oral fluid, urine, and breath alcohol test results, and integrates with DRUID, a one-minute functional impairment assessment that compares cognitive and psychomotor performance against individual personal baselines. The NEOTEST product range includes purpose-built hardware (Tamperloks, Split Cups, Multi-Panel Cups, Dip Cards, Oral Fluid tests) that operate natively within the NEOVAULT ecosystem. The platform holds ISO 27001, SOC 2 Type II, HIPAA, and GDPR certifications and integrates with EHS platforms including HSI Donesafe via API.

Neopharma operates a multi-revenue-stream model combining SaaS subscriptions (NEOVAULT/DRUID enterprise licensing) with hardware sales (NEOTEST kits) and OEM/API distribution through EHS platform and device-manufacturer partners. The go-to-market is enterprise-focused with quote-based pricing, direct field sales, and an API-first channel strategy. The company maintains offices in Perth (headquarters), Utah (USA), and Kuala Lumpur (Malaysia), with operational footprint across Australia, the United States, Canada, and Malaysia. The company is pursuing a NASDAQ listing as of late 2025, with Singapore fintech veteran Joo Seng Wong appointed as Board Advisor to oversee institutional strategy and global execution.

Neopharma Technologies firmographics

Firmographics
Name
Neopharma Technologies
Legal name
Neopharma Technologies
Website
https://neopharmatechnologies.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Neopharma Technologies provides a SaaS platform combining workplace drug and alcohol testing with AI-driven cognitive impairment screening for safety-critical industries including mining, ports, and aviation. The Perth-based company serves enterprises and channel partners across Australia, the US, and Southeast Asia.
Ownership category
akta.pro rank

Where Neopharma Technologies is headquartered

Location

Headquarters

HQ city
Perth
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Neopharma Technologies business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

  1. SaaS Platform Subscription: Cloud-based platform subscription for access to NEOVAULT and DRUID software. Includes dashboard access, API integrations, workflow management, and reporting capabilities. Subscription tiers likely based on organization size, number of sites, and feature requirements.
  2. NEOTEST Testing Kits: Sale of NEOTEST branded drug and alcohol testing devices including oral fluid tests, urine cups, dip cards, split cups, and Tamperloks devices. Devices are sold as NEOVAULT-enabled units with integrated software capability.
  3. Enterprise Licensing: Enterprise licensing for large multi-site organizations requiring standardized Fit-for-Duty workflows across multiple locations and contractor groups. Includes configuration, integration, and deployment services.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise SaaS platform pricing

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Neopharma Technologies product offering

Product offering

Core offering

Neopharma Technologies develops and sells NEOVAULT®, a device-agnostic point-of-care SaaS platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening for enterprise Fit-for-Duty workforce management. The platform combines AI-powered automated result interpretation (NEO-Vision), digital chain of custody, and multi-site enterprise scalability. It is complemented by the DRUID® impairment screening module and the NEOTEST® range of physical testing devices (oral fluid, urine cups, dip cards, split cups, Tamperloks) designed to operate natively within the NEOVAULT ecosystem.

Product overview

Neopharma Technologies offers NEOVAULT®, a device-agnostic point-of-care platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening into a unified Fit-for-Duty solution. The core NEOVAULT® platform is supported by add-on modules including NEO-Vision (AI image recognition for automated result interpretation), Digital Chain of Custody, Fit-for-Duty Decisioning, Enterprise Scalability, Compliance and Governance, BrAC Recording, and Digital Drug Testing workflows. The companion DRUID® module provides one-minute functional impairment assessment measuring cognitive and psychomotor performance against individual baselines. The NEOTEST® product family includes purpose-built testing devices (Tamperloks, Split Cups, Multi-Panel Cups, Dip Cards, Oral Fluid tests) that are NEOVAULT®-enabled out of the box. The combined NEOVAULT® + DRUID® ecosystem delivers comprehensive workforce impairment management for safety-critical environments.

Differentiator

Problem solved

Functional benefit

Brands

  • NEOVAULT: Digital drug testing and chain of custody platform for workplace fit-for-duty assessment
  • DRUID
  • NEOTEST
  • NEO-Vision

Products and services

  • NEOVAULT® Device-agnostic point-of-care SaaS platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening. Uses a smartphone or tablet app to capture and process test results in real time, creating a defensible digital audit trail with automated chain of custody, escalation rules, and compliance governance for enterprise workforce Fit-for-Duty programs.
  • DRUID® Impairment Screening One-minute functional impairment assessment delivered via smartphone or tablet. Measures cognitive and psychomotor performance (reaction time, processing speed, hand-eye coordination, balance, short-term processing capacity) against individual personal baselines to detect impairment from fatigue, illness, stress, medication, or substances. Each worker establishes a personal baseline through three supervised practice tests.
  • Tamperloks Drug Testing Cup Tamper-proof urine drug testing cup with interlocking lid and seal, unique triple chamber design that is 100% leak and odor proof. Includes temperature test strip and adulteration detection. Digitally enabled via NEOVAULT app with dynamic QR code and electronic chain of custody integration.
  • Drug Test Split Cup Dual specimen chamber urine test cup that simultaneously screens for up to 7 drugs and retains specimens for confirmation testing. Features leak-resistant hinged lid, angled opening, and specimen temperature indication with qualitative results in 5 minutes.
  • Multi Panel Drug Test Cups All-in-one urine-based multi-drug test cup supporting 1 to 14 panels per specifications. Quick, precise solution for on-site drug screening with results in minutes. FDA cleared and CLIA waived.
  • Dip Card Drug Tests CLIA Waived and FDA 510(k) cleared all-in-one urine-based drug test in dip card format. Supports 1 to 6 panels with simple non-invasive procedure and fast results in 5 minutes. Complies with AS/NZS 4308:2008 Australian Standard.
  • Drug Test Oral Fluid Oral fluid drug test complying with AS4760:2019 Australian Standard. Simple, fast, accurate detection of recent illicit drug use. Supports 1 to 14 panels and detects commonly abused drugs at concentrations below 75 ng/mL with non-invasive sample collection.

Quantifiable outcome

  • Complete digital chain of custody, eliminating paper-based documentation
  • +3 more outcomes

Companies that use Neopharma Technologies

Customer profile

Segments5 records

Ideal customer profiles3 records

Neopharma Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature6 records

Neopharma Technologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • HSI DonesafecoreTechnology or Integration · 24 February 2026API integration embedding Neopharma's NEOVAULT Fit-For-Duty workflows and DRUID impairment assessment into HSI Donesafe's cloud-based EHS safety management platform. The integration consolidates drug and alcohol testing and functional impairment assessments within the same governance system used for safety reporting, replacing fragmented checks with connected controls and strengthening audit trails. Addresses Australian WHS regulatory requirements.
  • Impairment SciencecoreTechnology or Integration · 1 February 2025Partnership to integrate NEOVAULT digital drug test reporting with AI-powered cognitive impairment assessment tools. Combines Neopharma's drug and alcohol testing platform with Impairment Science's cognitive assessment capabilities for comprehensive Fit-for-Duty screening.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Neopharma Technologies competitors and assessment

Company assessment

Broad incumbents

  • Dräger: German multinational manufacturer of safety and medical technology, including the DrugTest 5000 oral fluid drug testing system and Alcotest breath alcohol devices used in workplace and law enforcement settings. Directly comparable in workplace drug and alcohol testing hardware, with Dräger operating as a much larger incumbent across broader industrial safety.
  • Abbott Toxicology: Global diagnostics and medical device company with significant workplace drug testing operations through its eScreen and Alere Toxicology platforms. Comparable enterprise SaaS and drug testing offering but with a much broader diagnostics and device portfolio.
  • Quest Diagnostics: Major US medical laboratory services company with substantial employer solutions and workplace drug testing services. Comparable substance testing services but at much larger scale and with broader clinical and anatomic pathology focus.

Emerging players

  • Soberlink: Remote alcohol monitoring device and cloud platform used in legal, employment, and recovery contexts. Comparable digital impairment monitoring technology with similar enterprise and B2B workplace applications, though narrower in scope to alcohol rather than full substance and cognitive screening.

Direct peers

  • Omega Laboratories: Specialized drug testing laboratory offering hair, urine, and oral fluid testing for workplace, legal, and clinical markets. Comparable substance testing focus with similar turnaround-time and chain-of-custody requirements.
  • OraSure Technologies: Manufacturer of oral fluid diagnostic products including the Intercept drug testing device used in workplace and clinical settings. Directly comparable in vitro diagnostic substance manufacturing focused on oral fluid drug detection and workplace testing applications.
  • Psychemedics: Specialized hair drug testing laboratory providing workplace drug testing services to employers. Comparable substance testing focus with an alternative sample type and similar employer-customer profile.
  • SureHire: Canadian workplace drug and alcohol testing service provider offering fitness-for-duty assessments for employers across industrial sectors. Directly comparable employer-focused drug and impairment testing offering, primarily serving the Canadian market.
  • Cordant Health Solutions: Workplace drug testing and behavioral health services provider offering substance testing, medication monitoring, and behavioral health programs for employers and the justice system. Comparable employer drug testing services with overlapping customer base in safety-sensitive industries.
  • Premier Biotech: US-based manufacturer of urine and oral fluid drug testing devices, including multi-panel cups and dip cards used at point of care. Directly comparable drug testing device manufacturing with focus on workplace and clinical point-of-care products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Neopharma Technologies compliance and trust

Trust signal

Compliance4 records

Neopharma Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neopharma Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Neopharma Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neopharma Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neopharma Technologies

What does Neopharma Technologies do?

Neopharma Technologies develops and sells NEOVAULT®, a device-agnostic point-of-care SaaS platform that integrates drug and alcohol testing with cognitive and psychomotor impairment screening for enterprise Fit-for-Duty workforce management. The platform combines AI-powered automated result interpretation (NEO-Vision), digital chain of custody, and multi-site enterprise scalability. It is complemented by the DRUID® impairment screening module and the NEOTEST® range of physical testing devices (oral fluid, urine cups, dip cards, split cups, Tamperloks) designed to operate natively within the NEOVAULT ecosystem.

Is Neopharma Technologies a public or private company?

Neopharma Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neopharma Technologies founded?

Neopharma Technologies was founded in 2017. It employs 11 to 50 people.

Where is Neopharma Technologies based?

Neopharma Technologies is headquartered in Perth, Australia, in the Oceania region.

How does Neopharma Technologies make money?

Three revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are NEOTEST Testing Kits and enterprise Licensing.

Who are Neopharma Technologies's main competitors?

Broad incumbents on record are Dräger, Abbott Toxicology and Quest Diagnostics. Soberlink is listed as an emerging player. Direct peers are Omega Laboratories, OraSure Technologies, Psychemedics, SureHire, Cordant Health Solutions and Premier Biotech.

Does Neopharma Technologies have an API?

Yes. API integration available connecting NEOVAULT and DRUID into existing EHS platforms. The API enables real-time sync of drug, alcohol and impairment test results into the Donesafe platform. The integration roadmap allows organizations to embed Fit-For-Duty workflows into their existing safety ecosystem via API connections. Supports point-of-care manufacturer and distributor deployments across Australia and the United States.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesNeopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics PlatformNeopharma Technologies achieved ISO/IEC 42001:2023 certification for its NEOVAULT diagnostics platform, covering the AI management system's full lifecycle. The certification complements existing ISO/IEC 27001, SOC 2 Type II, GDPR, and HIPAA standards, strengthening governance for diagnostic and enterprise deployments.PR Newswire APACNeopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics PlatformNeopharma Technologies announced on August 27, 2026 that it has achieved ISO/IEC 42001:2023 certification for its Artificial Intelligence Management System, covering the design, development, deployment, operation, monitoring and maintenance of its NEOVAULT and myNEO software. The certification complements existing ISO/IEC 27001, SOC 2 Type II, GDPR and HIPAA compliance. Initial deployments focus on workplace health and drug and alcohol testing, with planned expansion into broader human health diagnostics.PR NewswireNeopharma Technologies Achieves ISO/IEC 42001:2023 AI Management System Certification for NEOVAULT® Global Diagnostics PlatformNeopharma Technologies achieved ISO/IEC 42001:2023 certification for its NEOVAULT diagnostics platform, covering the AI management system's full lifecycle. The certification strengthens its existing security and compliance framework, including ISO/IEC 27001, SOC 2 Type II, GDPR, and HIPAA. The platform is expanding from workplace health testing into broader human health diagnostics.openPR.comEmerging Sub-Segments Transforming the Clinical Research Organization Market LandscapeThe global clinical research organization (CRO) market is projected to reach $103.56 billion by 2030, growing at a compound annual growth rate of 9.6%, driven by demand for faster drug development, AI-powered trial optimization, and personalized medicine. In March 2024, India-based Veeda Clinical Research Ltd. acquired Ireland-based Heads to enhance its end-to-end service offerings from early discovery through post-commercial launch. Additionally, a February 2025 partnership was announced between Canada-based Neopharma Technologies and USA-based Impairment Science to integrate digital drug testing with AI-based cognitive impairment assessment.openPR.comEmerging Sub-Segments Transforming the Drug Screening Market LandscapeThe drug screening market is projected to grow to $19.2 billion by 2030, representing a compound annual growth rate of 14.5%, driven by advances in AI-powered screening analytics, portable testing devices, and stricter regulatory compliance. In June 2024, Premier Biotech acquired Desert Tox, LLC to strengthen its laboratory testing capacity and expand its reach in the US oral-fluid drug testing market. In February 2025, Canadian firm Neopharma Technologies partnered with US-based Impairment Science to integrate NEOVAULT digital drug test reporting with AI-powered cognitive impairment assessment tools.PR NewswireHSI Donesafe and Neopharma Technologies Announce API Integration for Fit-For-Duty WorkflowsHSI Donesafe and Neopharma Technologies Ltd announced a partnership to integrate Fit-For-Duty workflows into the Donesafe platform via an API integration roadmap. The integration embeds Neopharma's NEOVAULT® digital workflow and DRUID® one-minute functional impairment assessment directly into Donesafe's modular safety ecosystem, enabling organisations to manage drug and alcohol testing and impairment assessments within a unified, auditable governance framework. Australian WHS laws impose clear duties and personal liability on PCBUs and officers to manage safety-critical risks, driving demand for objective, documented Fit-For-Duty systems that regulators and boards can scrutinise.MorningstarHSI Donesafe and Neopharma Technologies Announce API Integration for Fit-For-Duty WorkflowsHSI Donesafe and Neopharma Technologies Ltd announced a partnership to integrate Neopharma's NEOVAULT® Fit-For-Duty workflows into HSI Donesafe's cloud-based EHS safety management platform via API. The integration consolidates drug and alcohol testing and functional impairment assessments within the same governance system used for safety reporting, replacing fragmented checks with connected controls and strengthening audit trails. The move addresses Australian WHS regulatory requirements, which impose personal liability on officers for failures to manage safety-critical risks including fatigue, impairment, and psychosocial hazards.PR NewswireNeopharma Technologies Ltd Announces Full Integration of NEOVAULT® with DRUID®Neopharma Technologies Ltd announced the completion of NEOVAULT's full integration with DRUID, creating a unified Fit-for-Duty platform for digital drug, alcohol, and impairment assessment in one seamless workflow. The integration is engineered to support large-scale deployments with point-of-care manufacturers and distributors across Australia and the United States, with API connections to leading EHSQ and OHS platforms. The platform combines operational speed, evidence-based readiness assessment, and security-first design to support regulated and safety-critical workplace environments.PR NewswireNeopharma Technologies Appoints Singapore Fintech Veteran and Serial Entrepreneur Mr. Joo Seng Wong as Board Advisor to Oversee Institutional Strategy and Global ExecutionNeopharma Technologies Ltd, an Australian-based digital health company specializing in AI-driven drug and impairment testing, announced the appointment of Mr. Joo Seng Wong, a Singapore fintech veteran and serial entrepreneur, to its Advisory Board. Wong brings over three decades of experience in finance, AI, and data infrastructure, including co-founding M-DAQ Private Ltd and serving as Co-Founder and CEO of Spark Systems, and will guide Neopharma's institutional strategy and global expansion ahead of its planned NASDAQ listing. The appointment is intended to strengthen Neopharma's execution discipline and investor engagement as it commercializes its NEOVAULT® Platform across occupational health, safety, and law-enforcement sectors.